The infection of carbapenem resistant klebsiella pneumoniae (CRKP) is increasingly serious.Based on the early experimental basis and relevant research background,this study intends to separate and purify the CRKP from the bronchoalveolar lavage fluid (BALF) of the clinical patients.Designed by checkerboard assay and time-kill assay(TKA),this study can explore the best combination therapy based on carbapenems.
1. Collect the BALF from patients diagnosed with CRKP infection in surgical intensive care unit(SICU)of Shanghai 10th people's hospital. 2. Separate and purify the BALF. Divide each CRKP into four treatment groups based on meropenem. 3.1 By checkerboard method and microdilution broth method,get the minimal inhibitory concentration (MICS) of two antibiotics,then calculate the fractional inhibitory concentration (FIC) index according to MIC results. 3.2 Observe the effect of two antibiotics on the growth of CRKP by TKA. 4.By the above two invitro experiments, analyze the data of the experimental results and get the best combination therapy based on carbapenems.
Study Type
INTERVENTIONAL
Purpose
TREATMENT
Masking
NONE
Enrollment
80
Fosfomycin and meropenem
Tigecycline and meropenem
Polymyxin B and meropenem
Shanghai 10th people's hospital
Shanghai, Shanghai Municipality, China
RECRUITINGthe fractional inhibitory concentration index (FICI)
By checkerboard method and microdilution broth method,get the minimal inhibitory concentration (MICS) of two antibiotics,then calculate the fractional inhibitory concentration (FIC) index according to MIC results. Evaluation index: FIC=0.5 , coordinating effect. 0.5 \< FIC \<1, adding effect; 1 \< FIC \<2, irrelevant.
Time frame: 24hours-36hours
the time-kill assay (TKA)
According to the Clinical and Laboratory Standards Institute,observe the changes of bacterial growth over time after different combination therapy.
Time frame: 36hours-48hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.